Read this topic

Imagine taking sildenafil with absolutely no sexual stimulation at all. Nothing much happens. That single fact is the key to the whole drug: sildenafil doesn't create an erection from nothing, it prolongs a signal that the body has already started, which is exactly why it matters so much what ELSE is influencing that same signal, particularly nitrates.

Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor: a drug that blocks the enzyme that would otherwise break down the signalling molecule behind an erection, so that signal lasts longer than it naturally would.

The most dangerous prescribing error associated with sildenafil is entirely avoidable with a careful medication history: co-prescribing it with nitrates. This is not a relative contraindication to weigh up, it is absolute, meaning the combination should never be used, because both drugs push the same final pathway in the same direction simultaneously, and the combined effect can be profound and life-threatening.

Sexual stimulation triggers the release of nitric oxide in the penile tissue, which activates an enzyme that produces cyclic guanosine monophosphate (cGMP), a signalling molecule that causes penile smooth muscle to relax. That relaxation allows blood to flow into and pool within the erectile tissue, producing an erection. Under normal circumstances, an enzyme called PDE5 breaks down cGMP over time, which is part of what allows an erection to subside. Sildenafil's entire mechanism sits at this one step: it blocks PDE5, so cGMP accumulates and persists for longer, prolonging the nitric-oxide-driven smooth-muscle relaxation and the resulting erection.

Nitrates, used in cardiology for angina (chest pain caused by reduced blood flow to the heart muscle), work by directly increasing nitric oxide availability, which raises cGMP through the same pathway sildenafil protects. Combining the two means both drugs are pushing cGMP levels up through the same final common pathway simultaneously, rather than acting independently, and the combined vasodilation (widening of blood vessels) can cause a sudden, severe drop in blood pressure that neither drug alone would cause. This danger applies whether the nitrate is prescribed, such as glyceryl trinitrate spray, or recreational, such as amyl nitrite ("poppers"), so history-taking before prescribing sildenafil must ask specifically and explicitly about any nitrate use in either category.

Erectile dysfunction has several distinct causes that need to be told apart before reaching for sildenafil. Psychogenic erectile dysfunction (arising from anxiety, relationship difficulty, or depression rather than a physical cause) often presents with preserved early-morning erections and a sudden, situation-specific onset, unlike the gradual onset typical of vascular causes. Antidepressant-induced sexual dysfunction, particularly with SSRIs, is thought to relate partly to their serotonergic effects on sexual response and is a recognised, often under-reported, reason patients stop taking an otherwise effective antidepressant. Vascular erectile dysfunction can itself be an early marker of underlying cardiovascular disease, so a first presentation outside the context of a new antidepressant should prompt basic cardiovascular screening, such as blood pressure, a lipid profile, and a glucose check, rather than an automatic sildenafil prescription.

Diagnosis of erectile dysfunction starts with a careful history distinguishing organic (gradual onset, absent morning erections, cardiovascular risk factors) from psychogenic (sudden onset, situation-specific, preserved morning erections) patterns, and a full medication review to identify a likely drug cause such as an SSRI. Baseline cardiovascular screening, blood pressure, lipid profile, and glucose, is appropriate for a new presentation, since erectile dysfunction can be an early marker of vascular disease rather than a purely psychological or drug-related problem.

Sildenafil is one recognised management strategy for antidepressant-induced erectile dysfunction, used either alongside the antidepressant or after a formal medication review, rather than automatically switching or stopping the antidepressant first-line. In practice, the sequence usually starts with asking directly about sexual side effects, since patients often do not volunteer them, considering a dose reduction or switch to an antidepressant with a lower rate of sexual dysfunction, and considering sildenafil as an adjunct where the antidepressant itself is otherwise working well and a switch is undesirable. Beyond the absolute nitrate contraindication, sildenafil requires caution rather than outright avoidance in several other groups: patients with significant cardiovascular disease where sexual activity itself carries exertional risk, patients on alpha-blockers (where the combined blood-pressure-lowering effect needs spacing between doses), and patients with hepatic or renal impairment, where dose adjustment may be needed. The BNF documents sildenafil's contraindications, including the absolute nitrate interaction, and is the standard prescribing reference to check before co-prescribing any vasoactive drug; Maudsley Prescribing Guidelines discuss management strategies for antidepressant-induced sexual dysfunction in more psychiatric-specific detail.

If a stem mentions ANY nitrate use, prescribed or recreational, sildenafil is an automatic "no," full stop, no risk-benefit discussion required. That single fact, tested from every angle, is the highest-yield point in this topic.

Sildenafil is a PDE5 inhibitor that prolongs cGMP-driven, nitric-oxide-dependent smooth-muscle relaxation rather than creating an erection independently, which is exactly why combining it with nitrates, which raise cGMP by a different route feeding the same endpoint, is never a safe treatment option.